scholarly journals Effect of a functional variant of tumor necrosis factor-β gene in temporomandibular disorders: A pilot study

2018 ◽  
Vol 33 (1) ◽  
pp. e22641 ◽  
Author(s):  
Kaan Yerliyurt ◽  
Ayse Feyda Nursal ◽  
Akin Tekcan ◽  
Nevin Karakus ◽  
Mehmet K. Tumer ◽  
...  
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Temporomandibular Disorders ◽  
Tumor Necrosis ◽  
Functional Variant ◽  
Necrosis Factor ◽  
Tumor Necrosis Factor Β

scholarly journals Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease

Blood ◽  
1992 ◽  
Vol 79 (12) ◽  
pp. 3362-3368 ◽  
Author(s):  
P Herve ◽  
M Flesch ◽  
P Tiberghien ◽  
J Wijdenes ◽  
E Racadot ◽  
...  
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Partial Response ◽  
Tumor Necrosis ◽  
Tnf Alpha ◽  
Necrosis Factor Alpha ◽  
Graft Versus Host ◽  
Factor Alpha ◽  
Necrosis Factor ◽  
Acute Graft

Abstract In a multicenter pilot study, 19 patients with severe acute graft- versus-host disease (aGVHD) refractory to conventional therapy and serotherapy with a monoclonal anti-interleukin-2 receptor antibody were treated by in vivo infusion of a monoclonal anti-tumor necrosis factor alpha (TNF alpha) antibody (B-C7). Ten patients were grafted from a genotypically identical sibling, five from an HLA-mismatched family member, and four from an HLA-matched unrelated donor. Before B-C7 treatment, 15 patients had grade IV and four had grade III GVHD. In all cases, patients received cyclosporine/methotrexate as aGVHD prophylaxis. Patients were administered increasing doses of antibody (from 0.1 to 0.4 mg/kg). The antibody was infused in bolus daily for 4 days and then every other day twice (6 doses). No side effects were observed during treatment regardless of the dose level used. Changes in peripheral blood cell counts occurred in 8 of the 19 patients and appeared to be unrelated to B-C7. No truly complete response was observed; eight patients achieved a very good partial response (42.6%) and six a partial response (31.5%). The treatment was ineffective in five patients (26.4%). When present, the response occurred early (less than 3 days). In the 14 responding patients, gut lesions responded best (100%), followed by skin (85%) and liver (35.7%) lesions. In 9 of 11 evaluable patients (81%), GVHD recurred when treatment was discontinued in a median delay of 3 days (range, 2 to 120 days). All except one died from aGVHD. Two patients did not experience GVHD recurrence and are still alive 13 and 18 months post-bone marrow transplantation. This pilot study shows that a monoclonal anti-TNF alpha antibody may be of benefit to some patients with severe refractory aGVHD, but is ineffective to prevent GVHD recurrence in the majority of cases.

Tumor Necrosis Factor-β and Hypercalcemia

1992 ◽  
Vol 7 (5-6) ◽  
pp. 409-417 ◽  
Author(s):  
Kazuaki Ishibashi ◽  
Masahiko Kodama ◽  
Shuichi Hanada ◽  
Terukatsu Arima
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Necrosis Factor ◽  
Tumor Necrosis Factor Β

scholarly journals Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study

2015 ◽  
Vol 13 (5) ◽  
pp. 963-966 ◽  
Author(s):  
Joshua D Fox ◽  
Katherine L Baquerizo-Nole ◽  
Brian R Keegan ◽  
Flor Macquhae ◽  
Julia Escandon ◽  
...  
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Venous Leg Ulcer ◽  
Necrosis Factor Alpha ◽  
Tissue Tumor ◽  
Adalimumab Treatment ◽  
Factor Alpha ◽  
Necrosis Factor

Rheumatoid Hand Joint Synovitis: Gray-Scale and Power Doppler US Quantifications Following Anti–Tumor Necrosis Factor–α Treatment: Pilot Study

Radiology ◽  
2003 ◽  
Vol 229 (2) ◽  
pp. 562-569 ◽  
Author(s):  
Clio Ribbens ◽  
Béatrice André ◽  
Stefaan Marcelis ◽  
Olivier Kaye ◽  
Luc Mathy ◽  
...  
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Power Doppler ◽  
Gray Scale ◽  
Doppler Us ◽  
Factor Α ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document